Abstract
Psychedelic-assisted therapies have re-emerged as a subject of increasing scientific and clinical interest in psychiatry, particularly in the context of persistent treatment gaps for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. Compounds, including psilocybin and 3,4-methylenedioxymethamphetamine, are being evaluated in controlled clinical trials and have demonstrated promising therapeutic effects when administered within structured psychotherapeutic frameworks. Emerging neurobiological evidence suggests that these agents may promote neural plasticity and facilitate cognitive and emotional flexibility, potentially enabling durable clinical improvement. Despite these advances, significant challenges remain, including regulatory uncertainty, methodological limitations in existing trials, ethical considerations related to patient vulnerability, and concerns regarding equitable access. This editorial examines the current state of psychedelic-assisted therapies, highlighting both their therapeutic potential and the critical considerations required for their responsible integration into mental health settings.